| 1.575 -0.045 (-2.78%) | 01-23 10:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.45 |
| Resists | First : | 1.79 | Second : | 2.1 |
| Pivot price | 1.59 |
|||
| Supports | First : | 1.54 | Second : | 1.38 |
| MAs | MA(5) : | 1.51 |
MA(20) : | 1.61 |
| MA(100) : | 1.98 |
MA(250) : | 1.57 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.9 |
D(3) : | 27.2 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 3.53 | Low : | 0.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRBU ] has closed below upper band by 42.8%. Bollinger Bands are 26.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.65 - 1.66 | 1.66 - 1.66 |
| Low: | 1.46 - 1.47 | 1.47 - 1.48 |
| Close: | 1.6 - 1.62 | 1.62 - 1.63 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Tue, 20 Jan 2026
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Wed, 14 Jan 2026
Caribou Biosciences (NASDAQ:CRBU) Shares Up 0.6% - Should You Buy? - MarketBeat
Tue, 13 Jan 2026
Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why - Yahoo Finance
Wed, 12 Nov 2025
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Mon, 03 Nov 2025
Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan
Mon, 03 Nov 2025
Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 8.45e+007 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 6,140 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3569e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 337.5 % |
| Return on Equity (ttm) | -32.5 % |
| Qtrly Rev. Growth | 9.29e+006 % |
| Gross Profit (p.s.) | 3.28 |
| Sales Per Share | -28.36 |
| EBITDA (p.s.) | -4.55191e+007 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 2.8 |
| Dividend | 0 |
| Forward Dividend | 6.5e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|